Last reviewed · How we verify
AZD7798
At a glance
| Generic name | AZD7798 |
|---|---|
| Also known as | Study Drug |
| Sponsor | AstraZeneca |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study Evaluating AZD7798 for Treatment in Crohn's Disease Patients With an Ileostomy (PHASE2)
- Positron Emission Tomography Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Patients With Crohn's Disease. (PHASE1)
- Phase IIa Study Evaluating AZD7798 in Crohn's Disease (PHASE2)
- AZD7798 Safety, Tolerability, and Pharmacokinetics After a Single Ascending and Repeat Dose Administrations to Healthy Subjects, and Patients With Crohn's Disease (PHASE1)
- Positron Emission Tomography (PET) Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Healthy Participants and Patients With Crohn's Disease (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AZD7798 CI brief — competitive landscape report
- AZD7798 updates RSS · CI watch RSS
- AstraZeneca portfolio CI